General Information of Drug (ID: DM1KD7U)

Drug Name
ABI-011 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM1KD7U

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiogenesis (AGG) TTB8Y9K NOUNIPROTAC Inhibitor [1]
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [3]
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Inhibitor [1]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [3]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Hepatocyte growth factor (HGF) DTT HGF 5.784 3.307 4.868 1.926
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
3 Company report (Indena)